Advertisement

Topics

Companies Related to "Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis" [Most Relevant Company Matches] RSS

07:08 EST 16th February 2019 | BioPortfolio

Here are the most relevant search results for "Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis" found in our extensive corporate database of over 50,000 company records.

Showing "Dose Ranging Study Evaluate Efficacy Safety SAR153191 REGN88" Companies 1–25 of 2,700+

Relevant

Protalex, Inc.

Protalex, Inc. is a clinical stage biopharmaceutical company that is developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including but not limited to, rheumatoid arthritis. Protalex’s lead product PRTX-100, which is formulated with a highly-purified form of staphylococcal protein A, has completed a Phase 1b...


SNBL USA, Ltd.

Headquartered in Everett, WA, SNBL USA, Ltd. offers a unique range of safety assessment services to support the drug development process. Managed and operated by a team world renowned for its wide-ranging NHP experience and expertise, we offer programs ranging from regulatory toxicology to customized study designs and disease models. Our specialized capabi...

ERT

Based in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries. The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. It is also a leading provider of centrali...


TheraCoat

TheraCoat is a specialty pharmaceutical company founded in 2004 by uro-oncologists and biomaterial specialists. TheraCoat’s Board of Directors and Scientific Advisory Board feature renowned scientific experts in the fields of urology, pharma top executives and experienced business veterans; among them Prof. Belldegrun and Mr. Hurvitz, both TEVA Board ...

Amarillo Biosciences Incorporated

Amarillo Biosciences, Inc., (ABI), is a biopharmaceutical company developing low-dose oral and topical interferon alpha. We are directing our research at the treatment of Behcet's Disease, and oral warts in HIV+ patients and chronic cough in idiopathic pulmonary fibrosis. Low-dose oral interferon is Fundamentally Different from high dose injectable interferon. In this site, we will show the fun...

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.

Kepivance™ (palifermin)

Kepivance™ (palifermin) is indicated to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients withhematologic (blood) cancers undergoing high-dose chemotherapy, with or without radiation, followed by bone marrow transplant. The safety and efficacy of Kepivance™ have not been established in patients with nonhematologic malignancies.

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...

Polynoma, Inc.

Polynoma, Inc. is an oncology-focused biotechnology company based in San Diego, the United States of America. Polynoma’s lead product candidate is the therapeutic vaccine POL 103A for the treatment of melanoma. The Phase 3 trial of POL 103A was initiated based on two randomized, controlled Phase 2 trials that showed statistically significant efficacy ...

TOPICA Pharmaceuticals, Inc.

TOPICA Pharmaceuticals, Inc. is a privately held clinical research stage pharmaceutical company focused on developing luliconazole for the treatment of onychomycosis, or fungal infections of the nail. The company is focused on conducting the Phase 2b/3 SOLUTION Study, a robust dose finding and proof of efficacy trial with luliconazole in onychomycosis with...

Hallux Incorporated

Hallux is developing an investigational micro-insert for subungual delivery and treatment of distal lateral subungual onychomycosis. The dosage form is biodegradable and delivers high concentrations of terbinafine hydrochloride directly and selectively to the site of infection over a period of time. Results from pilot studies are encouraging and suggest th...

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...

PreScience Labs, LLC

PreScience is a developmental stage bio-pharmaceutical company focused on the development of anti-cancer drugs. It has successfully completed preclinical mechanistic, in vitro and animal testing using intra-arterial delivery of its proprietary drug PSL-001. The FDA approved immediate enrollment of a Phase I, dose-escalating study, which PreScience intends ...

Jennerex, Inc.

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer -- an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combina...

RheoGene Inc

RheoGene is developing the RheoSwitch® Therapeutic System (RTS) for cell and gene therapy. RTS delivers therapeutic gene products in the patient to the right place, at the right time, and at the right dose. Despite advances in the understanding of the genetic and molecular basis of disease, there are no approved gene therapy products on the market today, in part because of the unmet need for effi...

Vascular Dynamics, Inc.

Vascular Dynamics develops catheter-delivered technologies to bring a better quality of life to patients who are resistant to conventional treatments for hypertension. Vascular Dynamics was one of nine companies chosen in 2012 by the FDA to participate in the Early Feasibility Study IDE Pilot Program. The company is conducting open-label, controlled, multi...

Coeur Scientific Inc.

Coeur Scientific Inc. is a contract development company committed to providing expert consultations and complete in vivo, in vitro preclinical study management in a state-of-the-art professional environment. These services produce detailed and thorough information on the efficacy and safety of new medical devices, procedures and therapeutic agents. Our primary objective is to deliver quality dat...

Advanced Biomedical Research Incorporated

Advanced Biomedical Research, Inc. (ABR) Corporate Headquarters is located in Pennington, New Jersey adjacent to the Princeton biopharmaceutical research corridor. ABR is a full service CRO offering an integrated package of customized services including clinical study protocol design, project management and study monitoring, quality assurance auditing, medical safety monitoring, biostatistics and...

Opsona Therapeutics Limited

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 ...

Guildford Clinical Pharmacology

Guildford Clinical Pharmacology Ltd (GCPL) has wide experience of efficient study designs in Phases 1 & 2 and develops new surrogate markers especialy for analgesics, the CNS and gastrointestinal drugs. We can use high tech equipment and the staff to run it correctly; recent examples being: 1) Gamma cameras for colonic transit measurements in a proof of efficacy study on a morphine antagonist an...

I3 Corporation

I3 is a La Jolla, California, based emerging medical device company focused on the design and development of innovative products for improved safety of the hospital environment. Founded in 2006, I3 has a strong proprietary portfolio of products ranging from needle-less injection site connectors, to safety syringes, and bio-diagnostic sampling devices. The fundamental driving philosophy behind ou...

Max-Planck-Institut für Plasmaphysik

Max-Planck-Institut für Plasmaphysik (IPP) at Garching and Greifswald provides training for young scientists, ranging from temporary assignments for undergraduates and practicals for students on completion of their intermediate diploma, through the allocation and supervision of diploma and PhD theses, to the presentation of comprehensive courses of graduate study with seminars, colloquia and stud...

TransOral Pharmaceuticals, Inc

TransOral Pharmaceuticals, Inc., is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. The Company's initial proprietary technology is being employed to accelerate efficacy and reduce drug dose in the development of therapeutics for the treatment of migraine and insomnia.

Evaluate, Ltd.

Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Evaluate supports life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Its services include EvaluatePharma, EvaluateClinicalTrials and EvaluateMedTe...

Quintiles Scotland

Safety PharmacologyQuintiles has safety pharmacology services to identify the potential adverse pharmacological effects of new chemical entities prior to first administration to man. Regulatory Safety Pharmacology packages Haemodynamics/ECG studies Cardiac action potential in vitro QT prolongationIon channels (e.g. HERG) Discovery SupportQuintiles pharmacologists can provide support in defining th...


More From BioPortfolio on "Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks